2. Astellas Pharma and INC Research

2. Astellas Pharma and INC Research:

In April Astellas Pharma and INC Research announced they were expanding their relationship. The partners etched out a three-year FSP alliance that will provide the Japanese pharma giant with various services including clinical monitoring, trial master file management, site start-up, study-feasibility activities and clinical data management.

FSP work has whetted the appetites of Big Pharma players like Eli Lilly ($LLY), Merck ($MRK) and Sanofi ($SNY), all of which have expressed interest in further using the model, which delves more into data management, according to William Blair equity analyst John Kreger in an Outsourcing-Pharma article in March.

In addition to the those services, INC established a dedicated business unit that will focus on the delivery and implementation of the FSP services for Astellas. The two estimate the relationship will reduce costs up to 40%, while providing time savings in the range of 10% to 20% over its course. 

2. Astellas Pharma and INC Research
Read more on

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.